Reports about bictegravir, the most recently approved integrase inhibitor, were included in an oral presentation and in several posters at CROI 2018.
A regimen consisting of only two drugs, the integrase inhibitor dolutegravir (Tivicay) and the NNRTI rilpivirine (Edurant), held up well as a maintenance approach in people with HIV who switched from more complex regimens.
A study showed viral control in the great majority of youth who took their regimen for five days but then skipped two, which may offer younger patients a novel way to keep HIV under control while addressing common adherence issues.
Biomarkers of immune exhaustion were associated with how long a patient was able to control HIV after treatment was interrupted, according to a study presented at CROI 2015.
Most antiretroviral treatment guidelines utilize a CD4+ cell count threshold for the initiation of therapy. Interventions that increase CD4+ cell counts may not only be clinically beneficial, they may also be able to prolong the time off of antiretro...